• Chest. 2014 Mar 1;145(3 Suppl):400A.

Session TitleCOPD Comorbidity PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Background: Chronic obstructive pulmonary disease (COPD) is a growing global epidemic especially in the developing world. It is increasingly being recognized that COPD is associated with various important comorbidities like cardiovascular diseases, osteoporosis, diabetes mellitus and metabolic syndrome. The mechanism linking COPD to systemic manifestations and comorbidities is not yet certain, but a potential mechanism to be systemic inflammation. Aim & objective: To determine the frequency of coexisting metabolic syndrome and to study the status of systemic inflammation in patients of COPD in ethnic Kashmiri population of India in view of high prevalence of COPD in them.MethodsMethods: Seventy nine stable COPD patients with different severity of airflow obstruction (GOLD stages I-IV) of both genders were investigated and accessed for the presence of metabolic syndrome as per IDF criteria. Systemic inflammation was accessed by measuring the serum hs-CRP and TNF-alpha levels in fifty five stable COPD patients which were compared with fifty five age and sex matched healthy controls.ResultsResults: The frequency of associated metabolic syndrome in patients of COPD in our study was 27.8% and this association was higher in females as compared to males (45.8% and 20% respectively).The levels of both the inflammatory markers i.e. hs-CRP & TNF-a were significantly higher in COPD patients as compared to age and sex matched healthy controls and the severity of systemic inflammation increased significantly with increase in the severity of COPD (p-value < 0.0001). The presence of metabolic syndrome within each GOLD stage of COPD resulted in significant increase in the level of systemic inflammation markers (p-value< 0.0001 ).ConclusionsConclusion: The present study revealed that a significant proportion of COPD patients have a coexistent metabolic syndrome and confirmed the presence of systemic inflammation in them. The coexisting metabolic syndrome is associated with an increase in the levels of systemic inflammatory biomarkers independent of lung function impairment.Clinical ImplicationsClinical implications: This study will give more insight in understanding COPD, which in turn will help better management of these patients including their co-morbidities in futureDisclosureThe following authors have nothing to disclose: Sonaullah ShahNo Product/Research Disclosure Information.

17 keywords...

hide…